Physician
Oncology
Dr. James H. Doroshow, MD
|
|
Give Review
James H. Doroshow works in the field of Oncology. He went to Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School has a rank of 1 in research and a 12 in primary care He received 1 awards: "Whos Who in Medicine and Healthcare". James Doroshow is also published. He has 99 publications published. The lastest publication: "Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast...'
Publications
- Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast...
- Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.
- Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California ...
- NADPH oxidases and cancer.
- Application of molecular profiling in clinical trials for advanced metastatic cancers.
- A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.
- Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
- ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses.
- Translational research in oncology-10 years of progress and future prospects.
- Validation of a Hypoxia-Inducible Factor-1α Specimen Collection Procedure and Quantitative ELISA in Solid Tumor Tissues.
- Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib.
- NOX1 causes ileocolitis in mice deficient in glutathione peroxidase-1 and -2.
- Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
- Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
- NADPH Oxidases: A Perspective on Reactive Oxygen Species Production in Tumor Biology.
- Criteria for the use of omics-based predictors in clinical trials.
- The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 genes.
- Wee1 kinase as a target for cancer therapy.
- An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology.
- Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.
- Molecular mechanisms underlying chronic inflammation-associated cancers.
- The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology.
- Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody.
- Cancer clinical trials--do we need a new algorithm in the age of stratified medicine?
- Cediranib for metastatic alveolar soft part sarcoma.
- Molecular targets in cancer therapy.
- Functional activity and tumor-specific expression of dual oxidase 2 in pancreatic cancer cells and human malignancies characterized with a novel monoclonal antibody.
- Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
- Activation of TLR4 Is Required for the Synergistic Induction of Dual Oxidase 2 and Dual Oxidase A2 by IFN-? and Lipopolysaccharide in Human Pancreatic Cancer Cell Lines.
- A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocyt...
- Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
- Safety and feasibility of targeted agent combinations in solid tumours.
- Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in...
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
- Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.
- Antiangiogenic approaches for the treatment of advanced synovial sarcomas.
- Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
- Opportunities and challenges in the development of experimental drug combinations for cancer.
- Genome-wide depletion of replication initiation events in highly transcribed regions.
- Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors.
- Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
- Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1? in advanced solid tumors.
- Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
- Up-regulation and Sustained Activation of Stat1 Are Essential for Interferon-{gamma} (IFN-{gamma})-induced Dual Oxidase 2 (Duox2) and Dual Oxidase A2 (DuoxA2) Expressi...
- Phase 0 trials: expediting the development of chemoprevention agents.
- Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
- Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors?
- Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
- Phase III clinical trial development: a process of chutes and ladders.
- Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.
- Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
- Adenocarcinoma of the small bowel: changes in the landscape?
- The National Cancer Institute Experimental Therapeutics program.
- Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.
- Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.
- Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.
- Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
- Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
- Five strategies for accelerating the war on cancer in an era of budget deficits.
- A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
- Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.
- Commentary: publishing cancer clinical trial results: a scientific and ethical imperative.
- Designing phase 0 cancer clinical trials.
- Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient.
- Phase 0 clinical trials: conceptions and misconceptions.
- Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
- Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
- Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
- Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
- Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MA...
- Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
- Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
- Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the So...
- A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
- Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity.
- Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
- Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
- CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
- Targeting EGFR in non-small-cell lung cancer.
- The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative ...
- Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy.
- Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
- Role of Se-dependent glutathione peroxidases in gastrointestinal inflammation and cancer.
- Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy.
- Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.
- Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
- A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
- Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes.
- Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
- Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacoki...
- A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
- Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
- Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
- Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
- Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
Schools
Harvard Medical School
Massachusetts General Hospital
National Cancer Institute
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Whos Who in Medicine and Healthcare
Education
-
Massachusetts General Hospital -
Harvard Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. Maurcio Burotto Pichun, MD |
|
|
Dr. Philip M. Arlen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley Lipkowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Howard L. Parnes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea B. Apolo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. C N. Coleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James X. Xu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph V. Boccia, MD
This Doctor is OpenDoctor Recommended.
|